Binds Hormone Or Other Secreted Growth Regulatory Factor, Differentiation Factor, Or Intercellular Mediator (e.g., Cytokine, Etc.); Or Binds Serum Protein, Plasma Protein (e.g., Tpa, Etc.), Or Fibrin Patents (Class 424/145.1)
  • Patent number: 10414825
    Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: September 17, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Kenneth Flanagan, Jeanne Baker, Theodore A. Yednock
  • Patent number: 10400022
    Abstract: A peptide that binds specifically to neuropilin-1 (NRP1) without binding to neuropilin-2 (NRP2) is provided. A fusion protein, a fusion antibody, small-molecule drug, a nanoparticle, or a liposome, which comprises the peptide, and a pharmaceutical composition for treating or preventing cancer or angiogenesis-related diseases, and a composition for diagnosing cancer or angiogenesis-related diseases are provided. A polynucleotide encoding the peptide that binds specifically to NRP1 and a method for screening the peptide that binds specifically to NRP1 are provided. An antibody heavy-chain constant region Fc-fused peptide binding specifically to NRP1 has the property of binding specifically to NRP1, and thus when it is administered in vivo, it accumulates selectively in tumor tissue, and widens the intercellular space between tumor-associated endothelial cells to promote its extravasation and increases its tumor tissue penetration.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 3, 2019
    Assignee: Ajou University Industry-Academic Cooperation Foundation
    Inventors: Yong Sung Kim, Ye Jin Kim
  • Patent number: 10391491
    Abstract: Methods and systems for isolating platelet-associated nucleated target cells, e.g., such as circulating epithelial cells, circulating tumor cells (CTCs), circulating endothelial cells (CECs), circulating stem cells (CSCs), neutrophils, and macrophages, from sample fluids, e.g., biological fluids, such as blood, bone marrow, plural effusions, and ascites fluid, are described. The methods include obtaining a cell capture chamber including a plurality of binding moieties bound to one or more walls of the chamber, wherein the binding moieties specifically bind to platelets; flowing the sample fluid through the cell capture chamber under conditions that allow the binding moieties to bind to any platelet-associated nucleated target cells in the sample to form complexes; and separating and collecting platelet-associated nucleated target cells from the complexes.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: August 27, 2019
    Assignee: The General Hospital Corporation
    Inventors: Mehmet Toner, Shannon Stott, Eduardo Reategui, Xiaocheng Jiang
  • Patent number: 10323086
    Abstract: The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgical pain, rheumatoid arthritis pain, and osteoarthritis pain.
    Type: Grant
    Filed: October 6, 2016
    Date of Patent: June 18, 2019
    Assignee: Rinat Neuroscience Corp.
    Inventors: Arnon Rosenthal, David Louis Shelton, Patricia Ann Walicke
  • Patent number: 10323067
    Abstract: Disclosed are peptides which specifically bind to preselected pre-miRNA or pri-miRNA targets, methods of down-regulating EMT in a cell using such peptides, and methods of preparing such peptides. Also provided are therapeutic compositions comprising peptides that specifically bind a preselected cancer marker which is a peptide or which is a pre-miRNA or a pri-miRNA and methods of treatment using the same.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 18, 2019
    Assignee: EVORX TECHNOLOGIES, INC.
    Inventors: Stephen V. Fiacco, Amanda N. Hardy, Terry T. Takahashi
  • Patent number: 10316083
    Abstract: The present invention relates to the finding that TL1A enhances differentiation of TH17 cells, and enhance IL17 secretion from TH17 cells. In one embodiment, the present invention provides a method of treating an inflammatory disease comprising determining the presence of a TL1A signaling profile, and treating the disease by administering a composition comprising a therapeutically effective dosage of one or more inhibitors of TL1A or TH17 cell differentiation. In another embodiment, the disease is characterized by TH17 differentiation.
    Type: Grant
    Filed: July 18, 2014
    Date of Patent: June 11, 2019
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Kathrin S. Michelsen, Stephan R. Targan
  • Patent number: 10314909
    Abstract: Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: June 11, 2019
    Assignee: Dyax Corp.
    Inventor: Daniel T. Dransfield
  • Patent number: 10307483
    Abstract: The invention relates to the formulation of pharmaceutical compositions of etanercept. The invention also relates to methods of removing buffer and of formulating pharmaceutical compositions of etanercept.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: June 4, 2019
    Assignee: AMGEN INC.
    Inventors: Monica Goss, Nicole Ball
  • Patent number: 10302655
    Abstract: The disclosure relates to a method for selecting, isolating and/or recovering a peptide or polypeptide from a library or a repertoire of peptides and polypeptides (e.g., a display system) that is resistant to degradation by a protease such as a protease found in the serum. Generally, the method comprises providing a library or repertoire of peptides or polypeptides, incubating the library or repertoire with a protease under conditions suitable for protease activity, and selecting, isolating and/or recovering a peptide or polypeptide that is resistant to degradation by the protease and has a desired biological activity. The selected peptides and polypeptides have utility as therapeutics, e.g., for treating disease in humans.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: May 28, 2019
    Assignee: Glaxo Group Limited
    Inventors: Carolyn Enever, Laurent Jespers, Malgorzata Pupecka-Swider, Ian Tomlinson
  • Patent number: 10265281
    Abstract: A method for the treatment or prevention of a cardiovascular event in a subject with atherosclerotic vascular disease comprising the step of: b) administering a therapeutically effective amount of a compound of formula (I), a known colchicine derivative and/or a salt thereof wherein: R1, R2, R3, R4, R9, R10, R11 and R12 independently represent hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, halogen, C1-4 haloalkyl, nitro, amino, C2-4 acylamino, C1-4 alkyl or dialkylamino, hydroxyl, C1-4 alkoxy, C1-4 alkylthio, a group of the formula —SO2N(Rx)2 or SO2Rx where Rx is C1-4 alkyl, C1-4 acyloxy, or optionally substituted phenyl, optionally substituted phenoxy; R7 and R8 independently represent hydrogen, C1-4 alkyl or C1-4 acyl; and R5?, R5?, R6? and R6? independently represent hydrogen, C1-4 alkyl, C2-4 alkenyl, C3-6 cycloalkyl, halogen, C1-4 haloalkyl, nitro, amino, C2-4 acylamino, hydroxyl, C1-4 alkoxy or C1-4 alkylthio a group of the formula —SO2N(Rx)2 or SO2Rx where Rx is C1-4 alkyl, C1-4 acylox
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: April 23, 2019
    Assignee: MURRAY AND POOLE ENTERPRISES LTD
    Inventor: Mark Nidorf
  • Patent number: 10266607
    Abstract: The present invention relates to an antibody that binds specifically to a tissue factor pathway inhibitor (TFPI), a nucleic acid encoding the antibody, a vector comprising the nucleic acid, a host cell transformed with the vector, a method for producing the antibody, and a pharmaceutical composition for treating hemophilia, which comprises the antibody as an active ingredient. The antibody of the present invention, which binds specifically to TFPI, can activate the extrinsic pathway of blood coagulation by inhibiting TFPI. Thus, the antibody of the present invention can be effectively used for the treatment of antibody-induced hemophilia patients and for the prevention of blood coagulation disease in hemophilia-A or hemophilia-B patients.
    Type: Grant
    Filed: December 29, 2015
    Date of Patent: April 23, 2019
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Dong-Sik Kim, Mi Jung Lee, Jae Chan Park, Sumin Lee, Heechun Kwak, SungHo Hwang, Hyung-Kwon Lim, Kisu Kim, Young Seoub Park, Junhong Jeong, Ki Joon Cho
  • Patent number: 10258667
    Abstract: The present mention relates to a method for detecting heart damage in a patient. The invention also relates to methods for treatment of patients identified as having heart damage. The invention further pertains to methods for evaluating the efficacy of an ongoing therapeutic regimen designated to treat a damaged heart in a patient.
    Type: Grant
    Filed: August 10, 2017
    Date of Patent: April 16, 2019
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Xinhua Yan, Anthony O. Caggiano
  • Patent number: 10260097
    Abstract: Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test identifies cancer subtypes that are responsive to anti-angiogenesis therapeutics and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any anti-angiogenic agent. This test may be used in different cancer types and with different drugs that directly or indirectly affect angiogenesis or angiogenesis signalling. In addition, the present invention may be used as a prognostic indicator for certain cancer types. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.
    Type: Grant
    Filed: June 4, 2012
    Date of Patent: April 16, 2019
    Assignee: Almac Diagnostics Limited
    Inventors: Denis Paul Harkin, Fionnuala Patterson, Claire Trinder, Eamonn J. O'Brien, Caroline Michie, Charlie Gourley, Laura A. Hill, Katherine E. Keating, Jude O'Donnell, Max Bylesjo, Steve Deharo, Vitali Proutski, Richard Kennedy, Timothy Davison, Andreas Winter, Andrena McCavigan
  • Patent number: 10233238
    Abstract: The present invention relates to anti-TNF alpha binding members and in particular to monovalent, high potency TNF alpha-binding antibody fragments being highly stable and soluble. Such binding members may be used in the treatment of inflammatory and other diseases as well as in diagnostics. Also provided are related nucleic acids, vectors, cells, and compositions.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: March 19, 2019
    Assignee: Cell Medica Switzerland AG
    Inventors: Abdijapar Shamshiev, Titus Kretzschmar
  • Patent number: 10221234
    Abstract: The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid P component (SAP), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, Alzheimer's disease, and type 2 diabetes.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: March 5, 2019
    Assignee: Glaxo Group Limited
    Inventors: Tejinder Kaur Bhinder, Susannah Karen Ford, Volker Germaschewski, Alan Peter Lewis, Mark Brian Pepys
  • Patent number: 10208110
    Abstract: Embodiments concern compositions and methods involving recombinant antibodies to histone post-translational modifications. The invention provides compositions and methods for histone methyltransferase assays. In certain embodiments, the compositions and methods involve a recombinant antibody that binds histone H3 fragment harboring biomarkers such as H3K9me3 mark, H3K4me3 mark, H3K36me3 mark, H3K27me3, H3K9me3 and H3S10phos or a recombinant antibody that binds histone H4 fragment harboring H4K20me3 mark.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: February 19, 2019
    Assignee: The University of Chicago
    Inventors: Takamitsu Hattori, Shohei Koide, Joseph Taft, Akiko Koide
  • Patent number: 10188600
    Abstract: The present invention relates generally to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. This invention is exemplified by a liquid formulation of a humanized anti-NGF antibody.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: January 29, 2019
    Assignee: Pfizer Inc.
    Inventors: Advait Vijay Badkar, Leigh Kristen Bohack, Kevin Roger King, Alanta Lea Lary
  • Patent number: 10188641
    Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: January 29, 2019
    Assignee: SARCODE BIOSCIENCE INC.
    Inventors: Thomas Gadek, John Burnier
  • Patent number: 10179816
    Abstract: The invention relates to novel pharmaceutical compositions including, as active ingredient, an antibody binding the human anti-Müllerian hormone type II receptor (AMHR-II) and an anticancer agent, as well as the therapeutic applications of these compositions.
    Type: Grant
    Filed: October 25, 2016
    Date of Patent: January 15, 2019
    Assignees: LABOTATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, ICM INSTITUT REGIONAL DU CANCER DE MONTPELLIER, I.N.S.E.R.M. (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER
    Inventors: Christine Gaucher, Isabelle Navarro-Teulon
  • Patent number: 10172921
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: January 8, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITÉ PARIS DIDEROT—PARIS 7, ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS
    Inventors: Alain Couvineau, Thierry Voisin, Nassima Messal, Eric Ogier-Denis, Xavier Treton
  • Patent number: 10166302
    Abstract: The present invention relates to a labeling composition for a cancer lesion, having a complex in which a pigment for straining living tissues, a radioactive isotope, or a combination thereof binds to macro aggregated albumin (MAA). A method for providing information regarding a cancer lesion site using the labeling composition for a cancer lesion. A labeling kit for a cancer lesion having the labeling composition for a cancer lesion; and a complex in which a pigment for straining living tissues binds to MAA included in the labeling composition for a cancer lesion. The labeling composition for a cancer lesion according to the present invention binds to a cancer lesion to detect a site, size, and the like of the cancer lesion in real time, thereby improving the success rate of a surgical operation for the cancer lesion and also preventing excessive loss of normal tissues.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: January 1, 2019
    Assignee: NATIONAL CANCER CENTER
    Inventors: Seok Ki Kim, Se Hun Kang, Seok Won Kim, So Youn Jung
  • Patent number: 10144804
    Abstract: The present invention provides, among other things, compounds that include a water-soluble and non-peptidic polymer as well as a maleimidyl group. The compounds are useful as, among other things, polymeric reagents.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: December 4, 2018
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Antoni Kozlowski, J. Milton Harris
  • Patent number: 10138477
    Abstract: The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface of S. cerevisiae cells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterization.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: November 27, 2018
    Assignee: MERCK PATENT GmbH
    Inventors: Ralph Guenther, Bjoern Hock, Stefan Becker, Laura Rhiel
  • Patent number: 10105415
    Abstract: The present invention provides compositions comprising granulocyte-macrophage colony-stimulating factor and fosfomycin for the treatment, prevention or alleviation of an inflammatory bowel disease such as Crohn's disease, ulcerative colitis or necrotizing enterocolitis of newborn and premature infants by administration of the compositions into the intestinal lumen.
    Type: Grant
    Filed: July 24, 2015
    Date of Patent: October 23, 2018
    Assignee: Reponex Pharmaceuticals A/S
    Inventors: Lars Heslet, Lars Otto Uttenthal
  • Patent number: 10106601
    Abstract: The present application relates to the field of leukemias, and more in particular to how P1 GF inhibition can help to treat Philadelphia chromosome positive (Ph+) leukemias. Methods are provided for treating Ph+ leukemias by administering P1 GF inhibitors. Also disclosed are uses of P1 GF inhibitors in the treatment of Ph+ leukemias, or for the preparation of a medicament against Ph+ leukemias.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: October 23, 2018
    Assignees: VIB VZW, Life Sciences Research Partners VZW
    Inventors: Peter Carmeliet, Sonja Loges
  • Patent number: 10087220
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SEQ ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Grant
    Filed: January 15, 2013
    Date of Patent: October 2, 2018
    Assignee: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Michele Aguera, Jean-Christophe Antoine, Marie-Francoise Belin, Jerome Honnorat, Veronique Rogemond
  • Patent number: 10053512
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: August 3, 2016
    Date of Patent: August 21, 2018
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG—UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH
    Inventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll
  • Patent number: 10016483
    Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition comprising a protein which inhibits the ligand of Uniprot #P05112 and/or the ligand of Uniprot #P35225 from binding to their respective receptors to a subject in need thereof. In some embodiments, the disorder is preferably associated with an increase of the Th2 immune response. In some embodiments, administration is preferably locally to the lung in order to treat, ameliorate or prevent allergic asthma, rhinitis, conjunctivitis, lung fibrosis, cystic fibrosis, chronic obstructive pulmonary disease, pulmonary alveolar proteinosis or adult respiratory distress syndrome.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 10, 2018
    Assignees: PIERIS PHARMACEUTICALS GMBH, ASTRAZENECA AB
    Inventors: Andreas Hohlbaum, Laurent Audoly, Beverly Koller
  • Patent number: 10017566
    Abstract: The methods and uses described herein relate to the treatment of age-related conditions, e.g. by administering an agent that inhibits the interaction of GDF11 and follistatin. In some embodiments, the agent can bind to an epitope of GDF11 as described herein.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: July 10, 2018
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventor: Richard Theodore Lee
  • Patent number: 9964543
    Abstract: Medicaments in the form of therapeutic molecules including inflammatory modulators are designed and selected. A target site is on Interleukin 13 (IL-13) in which a glycosaminoglycan (GAG) molecule or polyanionic glycoconjugate or anionic polysaccharide modulates IL-13 activity or function. The target site can include amino acids located in the AB loops and/or helix D of human IL-13 or its homolog or derivative. The IL-13 target site is used to design a medicament for modulating physiological processes. Therapeutic and prophylactic compositions can include the designed medicaments.
    Type: Grant
    Filed: June 18, 2013
    Date of Patent: May 8, 2018
    Assignee: GLYCAN BIOSCIENCES LLC
    Inventors: Deirdre Roma Coombe, Barbara Mulloy
  • Patent number: 9962407
    Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.
    Type: Grant
    Filed: November 9, 2006
    Date of Patent: May 8, 2018
    Assignees: Athersys, Inc., Oregon Health and Science University
    Inventors: Robert Deans, Wouter Van't Hof, Richard Maziarz, Magdalena Kovacsovics, Philip Streeter
  • Patent number: 9949992
    Abstract: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analog or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: April 24, 2018
    Assignee: DUKE UNIVERSITY
    Inventors: Kenneth W. Lyles, Cathleen S. Colon-Emeric, Christopher M. O'Connor, Dennis Abraham, Kent Nilsson, Howard Rockman, Graham Russell
  • Patent number: 9937240
    Abstract: The present invention relates to a composition for inhibiting fibrosis and more specifically, to a composition for inhibiting fibrosis, wherein the composition is effective in inhibiting fibrosis of tissue cells by containing a peptide derived from telomerase. The peptide according to the present invention exhibits an effect of inhibiting the progression of various kinds of fibrosis, including fibrosis due to occurrence of cancer, fibrosis due to the administration of chemotherapy anticancer drugs, fibrosis due to the exposure to radiation, or progressive fibrosis of tissues, including a TGF-? signaling procedure, and thus can provide a composition for anti-fibrosis or inhibiting fibrosis and a method for treating diseases due to fibrosis.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: April 10, 2018
    Assignee: GemVax & KAEL Co., Ltd.
    Inventor: Sang Jae Kim
  • Patent number: 9932403
    Abstract: The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Grant
    Filed: May 20, 2011
    Date of Patent: April 3, 2018
    Assignee: Ablynx NV
    Inventors: Christine Knuehl, Bjoern Hock, Robert Hofmeister, Gerald Beste, Hilde Adi Pierrette Revets, Frank Kamiel Delphina Verdonck, Sigrid Godelieve Victor Cornelis
  • Patent number: 9919051
    Abstract: The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least about 20 mg/ml, a tonicity modifier and a buffer, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders. Furthermore, a kit comprising the formulation of the invention is provided.
    Type: Grant
    Filed: October 31, 2013
    Date of Patent: March 20, 2018
    Assignees: Amgen Research (Munich) GmbH, Takeda GmbH
    Inventors: Thomas Urbig, Thomas Boehm, Wolfram Steinhilber, Michael Molhoj
  • Patent number: 9913902
    Abstract: The invention provides a method for producing a host cell protein-(HCP) reduced antibody preparation from a mixture comprising an antibody and at least one HCP, comprising an ion exchange separation step wherein the mixture is subjected to a first ion exchange material, such that the HCP-reduced antibody preparation is obtained.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 13, 2018
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Min M. Wan, George Avgerinos, Gregory Zarbis-Papastoitsis
  • Patent number: 9907819
    Abstract: The invention relates to therapy and methods of applying the therapy to a patient. The invention includes the introduction of immature dendritic cells into the patient and the introduction of anti-TNF antibody into the patient. The immature dendritic cells are introduced intratumorally and/or through vessel and the anti-TNF antibody is introduced intratumorally and/or through vessel and/or subcutaneously. The immature dendritic cells can be formed by collecting monocyte cells from the patient and culturing the cells in a culture medium. The invention can be effective to regress, reduce or eliminate tumor cells in tumor tissue of the patients, including metastasized tumors. Further, the treatment of the invention is effective in the absence of conventional therapy, such as radiotherapy and chemotherapy.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 6, 2018
    Inventor: Kenichiro Hasumi
  • Patent number: 9902769
    Abstract: Skin inflammation in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively binds IL-1?.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: February 27, 2018
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Patent number: 9896772
    Abstract: The present invention relates to a modular chemiresistive sensor. In particular, a modular chemiresistive sensor for hypergolic fuel and oxidizer leak detection, carbon dioxide monitoring and detection of disease biomarkers. The sensor preferably has two gold or platinum electrodes mounted on a silicon substrate where the electrodes are connected to a power source and are separated by a gap of 0.5 to 4.0 ?M. A polymer nanowire or carbon nanotube spans the gap between the electrodes and connects the electrodes electrically. The electrodes are further connected to a circuit board having a processor and data storage, where the processor can measure current and voltage values between the electrodes and compare the current and voltage values with current and voltage values stored in the data storage and assigned to particular concentrations of a pre-determined substance such as those listed above or a variety of other substances.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: February 20, 2018
    Assignee: INNOSENSE LLC
    Inventors: Maksudul M. Alam, Uma Sampathkumaran
  • Patent number: 9890194
    Abstract: An isolated protein containing a common epitope recognized by umbilical blood antibodies specific against enterobacteria, occurring in an extract of bacterial outer membrane proteins, and fragments thereof containing said common epitope, which can be used in medicine and pharmaceutics, particularly in the production of vaccines and diagnostic tests as well as affinity materials.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: February 13, 2018
    Assignee: WROCLAWSKIE CENTRUM BADAN EIT+ SP. Z O.O.
    Inventors: Anna Ewelina Jarząb, Danuta Witkowska, Edmund Ziomek, Andrzej Gamian
  • Patent number: 9856325
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 9856326
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 9849201
    Abstract: The present disclosure provides peptide constructs for diagnostic imaging and therapeutic applications, using pegylated peptides which exhibit specific binding for a target molecule of interest, such as a biomarker of a disease or disorder.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: December 26, 2017
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Gregory M Lanza, Samuel A. Achilefu, Grace Hufang Cui
  • Patent number: 9840560
    Abstract: The present invention relates to isolated monoclonal anti-EGFR antibodies, and to the use of such antibodies and antibody fragments to detect EGFR, particularly those expressed by cancer cells. The antibodies are useful in diagnostic as well as therapeutic indications. Methods, devices and kits for the immunodetection and immunotherapy of cells expressing EGFR is also encompassed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 12, 2017
    Assignee: ALPER BIOTECH LLC
    Inventor: Özge Alper
  • Patent number: 9834600
    Abstract: The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, the present invention relates generally to the treatment of eosinophilic bronchitis with an anti-IL-5 antibody or fragment thereof.
    Type: Grant
    Filed: March 27, 2009
    Date of Patent: December 5, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Fredrick E. Hargreave, Giampietro Ventresca
  • Patent number: 9833514
    Abstract: Provided are methods of treatment for tumors. In particular, methods are provided for use of a chemically modified IL-10 to treat tumors.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: December 5, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Martin Oft, Catherine Sheppard, John Brian Mumm, Lingling Wu
  • Patent number: 9808525
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: November 7, 2017
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Patent number: 9801942
    Abstract: The invention provides stabilized aqueous pharmaceutical etanercept compositions suitable for long-term storage of etanercept, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: October 31, 2017
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Brian Murphy
  • Patent number: 9796779
    Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: October 24, 2017
    Assignee: MedImmune Limited
    Inventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
  • Patent number: 9783607
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: October 10, 2017
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet